Despite the proven efficacy of acute and maintenance pharmacotherapy in schizophrenia, practical methods for identifying patients who require continuous treatment to prevent relapse have not been established. We hypothesized that a pathologic overactivity of mesolimbic and mesocortical dopamine neural systems, that mediates positive psychotic symptoms in the acute phase of the illness, persists in some outpatients who are vulnerable to relapse despite appearing clinically stable. To test and determine if putative measures of central nervous system dopamine activity predict outcome, 41 stable outpatients receiving neuroleptic maintenance treatment underwent provocative tests with methylphenidate in a randomized KEY WORDS: Schizophrenia, relapse; Dopamine; Methylphenidate Despite the proven efficacy of neuroleptic drugs in preventing psychotic relapse, much remains to be done to maximize their benefIt to risk ratio in the context of maintenance treatment strategies (Gardos et al. 1978; Schooler 1991) . Numerous placebo (PBO) controlled maintenance treatment studies have shown an aver age of a 40% difference in relapse rates favoring neu roleptic treatment (Davis 1975; Kane et al. 1987) . How- 655 Avenue of the Americas, New York, NY 10010 double-blind placebo controlled design in which behavioral, neuromotor, biochemical, and cardiovascular responses were measured. Patients were then withdrawn from medication and monitored for 52 weeks, or until relapse. The results indicate that psychotic symptoms and their activation by methylphenidate, and the presence of tardive dyskinesia are associated with each other and with a higher risk of relapse. These findings partially support our hypothesis and offer potentially useful measures for the identification of candidates for reduced dose neuroleptic maintenance treatment strategies in schizophrenia. {Neuropsychopharmacology 11: 107-118, 1994J 
double-blind placebo controlled design in which behavioral, neuromotor, biochemical, and cardiovascular responses were measured. Patients were then withdrawn from medication and monitored for 52 weeks, or until relapse. The results indicate that psychotic symptoms and their activation by methylphenidate, and the presence of tardive dyskinesia are associated with each other and with a higher risk of relapse. These findings partially support our hypothesis and offer potentially useful measures for the identification of candidates for reduced dose neuroleptic maintenance treatment strategies in schizophrenia. {Neuropsychopharmacology 11:107-118, 1994J ever, it is apparent that signifIcant numbers of patients still relapse while taking medication, whereas others taking PBO do not. In addition, studies have demon strated that many patients can be successfully treated with "low doses" of neuroleptics (less than 25% of the standard dose range) (Kane et al. 1983; Marder et al. 1987; Hogarty et al. 1988 ) whereas targeted/intermit tent neuroleptic treatment strategies (Pietzcker et al. 1986; Jolley et al. 1989; Carpenter et al. 1990; Herz et al. 1991) may be employed in patients who refuse con tinuous maintenance treatment. These studies have demonstrated that the increased risk of relapse as sociated with low dose and targeted treatment may be offset by fewer behaviorally manifest extrapyramidal side effects (e.g., akinesia, akathisia) and improved so cial functioning (Kane et al. 1985; Marder et al. 1987; Carpenter et al. 1990; Herz et al. 1991) . In addition, studies of tardive dyskinesia (TO) have shown that there is a TO incidence of approximately 5% per year of neu roleptic exposure (Kane et al. 1985a) . Preliminary evi dence from treatment studies indicates that patients receiving reduced dose treatment had lower ratings of abnormal movements compared to patients who re ceived continuous standard dose medication (Kane et al. 1985b) .
The therapeutic and prophylactic value of neurolep tic drugs is evident when examining groups of patients, but there are no proven clinical measures that identify the individual patients at greatest risk of relapse, or that measure those who are candidates for drug withdrawal, or reduced dose maintenance treatment strategies. Con sequently, standard clinical practice has been to main tain patients on standard doses of neuroleptic drugs indefmitely. This practice is not optimal for all patients.
Previous studies have suggested the utility of vari ous measures as predictors of relapse (Lieberman and Kane 1986c) . The most promising of these are measures of central nervous system (CNS) dopamine (DA) activ ity including plasma prolactin levels (PRL) (Brown et al. 1981; Zander et al. 1981; Wistedt et al. 1982; Lieber man et al. 1986a) , growth hormone response to DA agonist stimulation (Cleghorn et al. 1983; Mueller Spahn et al. 1984; Lieberman et al. 1986 ), plasma neu roleptic levels (Brown et al. 1982; Brown et al. 1985; Marder et al. 1987) , pHV A (Davidson et al. 1991) and behavioral response to DA agonist stimulation (van Kammen et al. 1982; Davidson et al. 1987; Lieberman et al. 1987b; Angrist et al. 1981) . The latter line of inves tigation is based on the fi.nding originally demonstrated by Janowsky et al. (1973) and Angrist et al. (1980) that a single or brief administration of a DA agonist can in duce psychotic symptoms in schizophrenics in doses that would not induce psychosis in normal subjects (Lie berman et al. 1987a ). This increased vulnerability to the psychotogenic effects of indirect DA agonists in patients with schizophrenia is believed to be a state dependent phenomenon produced by increased DA neuronal ac tivity (Janowsky et al. 1973; van Kammen et al. 1982) . We hypothesized that this reflects the pathologic over activity of mesolimbic and mesocortical DA neural sys tems that characterizes the acute phase of the illness and can persist in some stable outpatients whose be havioral symptoms have remitted (Lieberman et al. 1987b) . Such patients, although appearing to be clini cally stable, are hypothesized to be physiologically un stable and prone to symptom exacerbation if pharmaco logically perturbed by DA agonist administration, or the discontinuation, or reduction of dopamine antag onism. Thus, behavioral response to a provocative test with a DA agonist could be an indicator of instability and of increased risk of relapse, particularly under conditions of neuroleptic dose reduction or discon tinuation.
This study was designed to test if behavioral re sponse to methylphenidate (METHYL), an indirect act-ing DA agonist, predicts outcome, and to assess the rela tionship of other indices of CNS DA activity to behavioral response and outcome in stable outpatients who are candidates for withdrawal from neuroleptic mainten ance treatment. Methylphenidate is a nonarnphetamine like psycho stimulant that binds to the DA transporter and inhibits the reuptake of DA by presynaptic ne u rons (McMillen 1983) . It has been found to have more potent psychotogenic effects than amphetamine-like stimulant drugs (Janow sky et al. 1976; Lieberman et aI. 1987a) . Our primary hypothesis was that patients who have psychotic symptom activation with methylpheni date would relapse more rapidly and in greater propor tion than patients who did not. In addition, we hypoth esized that other measures that were regulated, at least in part, by DA systems (growth hormone [GH1, PRL, pHV A, blink rate, and TD) would exhibit enhanced re sponses to methylphenidate in patients with psychotic symptom activation compared to patients who don't. We have previously published the preliminary results of selected variables from the study Lieberman et al. 1987b ) and now report the full results of the completed study.
SAMPLE AND METHODS

Sample
All patients in the Aftercare Service of the Hill side Hos pital, division of Long Island Jewish Medical Center, Glen Oaks, NY were screened for study eligibility. The study protocol had been reviewed and approved by the Institutional Review Board of the Medical Center. Eligi ble patients met the following criteria:
1. They had a diagnosis of subacute, subchronic, chronic schizophrenia, or schizoaffective disorder according to the Research Diagnostic Criteria (Spit zer et al. 1977 ). 2. Their ages ranged from 18 to 50 years. 3. They had no history of serious neurologic or en docrine disorders and no current serious medical conditions. 4. They were in a state of relative remission as defi.ned by the following ratings on items from the Sched or Affective Disorders and Schizophrenia-Psy chosis and Disorganization (SADS-PD) items: (a) a rating no greater than 2 for severity of delusions (only suspected of being present by the rater); (b) a rating no greater than 2 for severity of hallucina tions (only suspected of being present by the rater); (c) a rating no greater than 3 for incoherence (a few defi.nite instances of impairment in understand ability, but they are never gross); (d) a rating no greater than 3 for bizarre behavior (strange be havior, but not obviously crazy); and (e) catatonic motor behavior not present. In addition, a sum of scores on factors III (conceptual disorganiza tion, grandiosity, hallucinatory behavior, unusual thought content), IV (tension, mannerisms and posturing, excitement), and V (hostility, suspi ciousness, uncooperativeness) of the brief Psy chiatric Rating Scale (BPRS) was lower than 24. 5. They were stable at the above level of remission for at least six months while receiving medication and wanted to discontinue neuroleptic main tenance treatment. 6. They were willing and able to give informed consent.
Forty-eight patients wh' o met the inclusion criteria provided informed consent and entered the study. Seven of these patients were excluded from the data analyses for the following reasons: two had been with drawn from the study because new information led to revision of their diagnoses (revised diagnoses were confrrmed by nonstudy personnel blind to the patients' study outcomes); one patient relapsed prior to the frrst infusion procedure; and four dropped out while going through the infusion phase. The sample employed for analyses included 25 males and 16 females with a mean age of 28.9 ± 6.2 years. Sixty-seven percent of the pa tients were white and 33% were black. Seventy-three percent of patients were diagnosed with schizophreDopamine and Relapse in Schizophrenia 109 nia and 27% with schizoaffective disorder, mainly schizophrenic by Research Diagnostic Criteria (Spitzer et al. 1977 ). Patients had a mean age at onset of 22.6 ± 4.5 years and 2. 7 ± 2.1 prior hospitalizations. All were stable outpatients living in the community with a mean ± SO duration of remission of 96 ± 48 weeks and low levels of residual symptomatology. Mean ± SO rating scale item scores were at baseline for the BPRS 1.3 ± 0.3, the SAOS-PO 1.3 ± 0. 7 and the Clinical Global Im pression (CGI) severity item 1.9 ± 0.7. At study entry 51 % of patients were receiving oral neuroleptics and 49% were receiving long-acting injectable neuroleptic treatment. The mean (SO) dose in chlorpromazine equivalents was 426 ± 712 mg/d. Fifty-four percent of the patients had TO defIned as a global rating of "mild" or greater on the SOS. The high rate of TO was because stable patients with neuroleptic induced side effects are candidates for drug withdrawal and therefore were selectively referred for the study. In addition, because diagnoses of TO were based on examinations of patients while taking and not taking medications, any covert dyskinesias were likely to be unmasked.
Procedures
The study design is illustrated in Figure 1 .
Infusions
Patients underwent two infusions, one of METHYL and one of PBO, in randomized order under double blind conditions, one week apart. Prior to the frrst procedure, patients underwent a physical exam and an EKG. Dur ing the infusion procedures, the cardiac rhythms of pa tients were continuously monitored. Six patients who entered the study during an earlier protocol design re ceived only one set of infusions (METHYL and PBO), 20 days after neuroleptic discontinuation. Twenty-seven patients had the complete set of four infusions (two while receiving neuroleptic maintenance treatment and two after withdrawal from it). The withdrawal period prior to the second set of infusions was 20 days for pa tients on oral medication and 42 days from long-acting injectable medication. Eight patients had the infusions while on medication because they relapsed during the withdrawal period prior to the second set of infusions.
A standardized protocol was used for all infusions. The procedure was conducted between 8:30 A.M. and 12:00 P.M. in the biologic studies laboratory. After an all-night fast (and at 12 hours after taking their last dose of medication during on-medication procedures), the patient underwent a brief standardized examination for TO that was scored on the Hillside modifIed version of the Simpson Dyskinesia Scale , and then was placed in a comfortable supine position on a hospital bed. An indwelling catheter (19-gauge scalp vein) was inserted into a forearm vein, secured, and connected to a slow-running infusion system kept patent with heparinized saline solution. After an adap tation period of 45 minutes, blood samples were col lected through the catheter at 20-minute intervals for 60 minutes. Blood pressure, pulse rate, and blink rate were also measured. During this period, a preinfusion evaluation was completed by a research psychiatrist and scored on the SADS-PD, the BPRS, and the eGI rating scales.
After the preinfusion period, 0.5 mg/kg of METHYL, or an equivalent volume of saline solution was ad ministered intravenously in the contralateral arm over a period of 120 seconds. The patient was interviewed informally and observed continuously for 80 minutes following the infusion. The patient's highest level of behavioral symptomatology was rated on every be havioral item of the SADS-PD and BPRS for the total postinfusion period. Postinfusion blood pressure and pulse rate were monitored at ten-minute intervals; blood samples were collected at 20-minute intervals; blink rate was measured at 30-minute intervals. On completion of the postinfusion period, the catheter was withdrawn and the TO examination was repeated. At the end of the procedure, patients were given an in tramuscular dose equivalent to 250 mg of chlorproma zine of whichever neuroleptic drug they had most re cently been treated with, along with 2 mg of benztropine by mouth to counteract any activated symptoms.
Biochemical Measures
Five cc samples of whole blood were collected in heparinized tubes at room temperature at -45, -25, and -5 minutes preinfusion and 20, 40, 60 minutes postinfusion for determination of PRL and GH. All specimens were centrifuged at 5,000 RPMs. The plasma was separated into polypropylene tubes and immedi ately frozen at -200e until analysis. Eight cc samples of whole blood were collected in glass tubes contain ing EDTA and sodium metabisulfate at -5 minutes preinfusion and 40 and 60 minutes post infusion for HV A determination. All specimens were centrifuged at 5,000 RPMs for 15 minutes, and then the plasma was pipetted into glass tubes and immediately frozen at -200e until analysis.
Plasma PRL was measured by a double antibody radioimmunoassay (Sinha et al. 1973) . Prolactin stan dard (hPRI-RP-l) and the primary antiserum were do nated by the National Pituitary Agency. The labeled PRI-1 125 was purchased from New England Nuclear and repurifIed before use on a G-I00 Sephadex column. Antirabbit globulin serum was used to separate the bound and free fractions. Samples were assayed in duplicate. The intraassay and interassay coefficients of variation were 6.4% and 6.9% at 3.76 ng/ml; 3. 8% and NEUROPSYCHOPHARMACOLOGY 1994-VOL. 11, NO.2 5.7% at 27.0 ng/ml; and 2.0% and 3.5% at 46.3 ng/ml . Growth hormone was analyzed by radioimmunoassay (Glick et al. 1963) . The coefficients of variation within and between assays were for concentrations of 1.5 ng/ml at 9.6% and 12.4%; 7.5 ng/ml at 3.2% and at 3.8%; 33 ng/ml of 2.6% and at 3.9%. For the quantifIcation of plasma HV A, we adapted the method of Fri et al. (1974) using gas chromatography mass spectroscopy (GCMS).
Using pentadeuterated HV A as interval standard, 0.5 ml of plasma was diluted with aqueous buffer (pH 4.0) and extracted with ethyl acetate. The ethyl acetate was then placed in a tapered tip glass tube containing 50 w pentafluoropropionic anhydride (PFPA) and taken to dryness via a vacuum centrifuge at 40°C. PFPA and trifluoroethanol (4:1) were added and incubated at 75°( for 15 minutes and again taken to dryness. The residue was redissolved in 30 w cyclohexane. One w was then injected into a capillary GeMS using the cold trapping procedure with the mass spectrometer operated in the electron impact mode utilizing simultaneous ion monitoring of the molecular ion 410 m/z and the inter nal standard molecular ion 415 m/ z. Secondary ions at 283 m/z and 288 m/z were monitored for additional specifIcity. The method has an intra assay and interas say coefficient variation of 4.2% and 6.1%. Standard curves are linear through 50 ng/mL with negligible in tercept and a lower limit of sensitivity of 0.5 ng/mL.
Deftnition of Behavioral Response
Infusion responses were classifIed according to the fol lowing predetermined criteria: A positive response was defIned as an increase of at least two scale points above the threshold of any of the critical SADS-PD items used to defIne remission, or an eight-point or greater increase from the total preinfusion BPRS scores on eight critical items (conceptual disorganization, bizarre behavior, grandiosity, hostility, suspiciousness, hallucinations, unusual thought content, and uncooperativeness). An increase of one scale point above the SADS-PD item thresholds or a six-point increase in the BPRS critical items score was a questionable response. True-posi tive responders were those who had positive change scores to METHYL only (and not PBO). Negative responders were those who had negative responses to all infusions.
Follow-Up
Patients were seen weekly by their treating psychiatrist during the drug washout period between infusions and for ten weeks following the infusions and for ten weeks following the infusions; thereafter, they were seen bi weekly. The treating psychiatrists were blind to the pa tient's infusion response. Assessments at each clinic visit were scored on the BPRS, a prodromal symptom on all subjects who had available pairwise data (* p < .05; ** P < .01).
scale adapted from Herz and Melville (1980) and CGI. Prodromal symptoms are nonpsychotic symptoms in cluding anxiety, sleep disturbance, and irritability that have been hypothesized to precede psychotic relapse (Carpenter et al. 1987; Herz and Melville 1980) . Patients were maintained entirely drug free for 52 weeks, or until manifestations of psychopathology recurred. To evalu ate the predictive validity of prodromal symptoms, criteria were established to defIne prodromal status. If patients met prodromal status criteria, they were ran domly assigned to treatment for eight weeks with 10 mg/d of fluphenazine hydrochloride by mouth, or PBO under double-blind conditions. If the patient was sta ble and no longer exhibited prodromal symptoms by the end of this period, medication was discontinued. If at any time patients exhibited symptoms of relapse, they were treated as clinically indicated. Five of the pa tients in this study exhibited symptoms meeting the prodromal criteria. Because an unbalanced randomi zation schedule was employed, only one patient was as signed to active fluphenazine treatment after pro dromal symptoms developed; thus, the course of the PBO-treated patients could be monitored. (Results of the prodromal and treatment-outcome portion of the study will be presented in a separate report.) Relapse was defIned as an increase of at least two scale points above the threshold on any of the critical SADS-PD items used to defIne remission, and/or a ten point increase or greater from the baseline scores of the critical BPRS items, and a CGI scale improvement item rating of six (much worse) or greater.
Statistical Methods
Analyses of preinfusion (basal unstimulated) and postinfusion (stimulated) measures with and without neuroleptic drugs were done using paired t tests. Mul tivariate repeated-measure analyses of variance were used to assess the effects of neuroleptic exposure and METHYL infusion on preinfusion and postinfusion scores. Chi-square analyses with the Yates correction were performed on categorical variables. Survival anal yses were done for the time to relapse across groups defIned by behavioral response to methylphenidate and by the presence of TO. Cox proportional hazards regres sion analysis was used to examine the effects of con tinuous measures on time to relapse. Survival analysis is particularly appropriate for the data on time to re lapse because the exact survival times are unknown for individuals who either did not complete the study, or are still stable at the end of the study period. Survival analysis takes such censored data into account when it estimates survival time (Lee 1980) . Figure 2 . To analyze for drug effects and interactions, repeated measures anal ysis of variance was performed on the preinfusion and postinfusion measures over the four infusion condi tions. The within subject factors included in the analy- sis were neuroleptic status (on versus off neuroleptic), METHYL (PBO versus METHYL), and infusion status (pre infusion versus postinfusion values), and the in teractions involving these factors. As indicated by signifIcant interactions between METHYL and infusion status, METHYL infusion resulted in greater increases as compared to PBO in BPRS critical items (F = 16.8, df = 1,23, P < .001), ab normal movements on the 50 S (F = 27.4, df = 1,14, P < .001), systolic blood pressure (F = 99.3, df = 1,22, P < .001), pulse rate (F = 85.0, df = 1,22, P < .001), growth hormone (F = 18.3, df = 1,23, P < .001) and prolactin (F = 9.0, df = 1,23, P = .006).505 ratings were higher (pre infusion and postinfusion on PBO and METHYL) when patients were off neuroleptics as com pared to when they were on neuroleptics (F = 7.3, df = 1,14, P = .017). In addition, an interaction between neuroleptic, METHYL, and infusion status was seen when the global 50 S rating was examined (F = 7.0, df = 1,14, P = .019). Prolactin values were lower when off neuroleptics (F = 12.3, df = 1,23, P = .002). Postin fusion plasma HV A levels were nonsigniflcantly de creased from preinfusion levels. This decline appeared to be greater in response to METHYL and in the off neu roleptic condition.
RESULTS
Behavioral and physiologic responses to methylpheni date and placebo are shown in
Cardiovascular responses peaked within 20 min utes of METHYL administration and gradually subsided over the remainder of the procedure and in all cases were within physiologically safe and tolerable ranges (Robinson et al. 1988) .
Using the a priori deflnition previously described to classify behavioral response to the infusions, there were 26 (63%) negative, seven (17%) positive, and eight (20%) questionable responders (Table 1) . No patient had a positive or questionable response to PBO. Among pa tients who had infusions both on and off neuroleptics, the rate of positive and questionable response was 33% in the off neuroleptic condition compared to 22% on neuroleptics, but this difference was not statistically signifIcant (X? = 1.3, df = I, P = .38). Four patients who had negative responses to the on neuroleptic METHYL infusion converted their response status in the off neuroleptic METHYL infusion -three to a ques tionable response and one to a positive response. One patient who had a questionable response to the on neu· roleptic METHYL infusion converted to a positive re sponse in the off neuroleptic infusion. Seventeen pa tients had negative responses, two had positive responses, and two had questionable responses to METHYL infusions in both conditions. Because the positive and questionable responders to METHYL were widely separated from the negative responders on the magnitude of their BPRS critical item changes, they were combined for the outcome analyses. Hereafter, this combined group is referred to as positive responders. Positive (plus questionable) and negative respon ders showed few diff erences on demographic and clin ical variables. There were more female positive responders (56% as compared to 24% among males) (X? = 3.1, df = I, P = .079). Positive responders were slightly more symptomatic at baseline scoring 1.4 (.30) There was no diff erence in the number of patients who entered the study on fluphenazine decanoate in the positive and negative responding groups. Positive responders were younger than negative responders at their fIrst psychotic treatment (18.4 [6.1] versus 22.7 [5.5] yrs; t = 2.3, df = 37, P = .027). Eighty percent of the positive responders had TO compared to 38% of the negative responders (X? = 5.0, df = I, P = .025). Posi tive and negative responders did not exhibit signifIcant differences in the biochemical or cardiovascular basal preinfusion measures. However, basal pHVA was higher prior to the off neuroleptic infusions in patients who activated with METHYL compared to nonactiva tors (20.4 ng/ml [15.9] versus 8.4 ng/ml [4.3] respec tively), but was similar prior to the on neuroleptic infu sions (9.4 ng/ml [5.2] versus 9.7 ng/ml [4.0] respectively) resulting in a signiflcant METHYL response by neu roleptic status interaction (F = 7.1, df = 1,7, P = .032).
Of the 26 negative responders, six did not complete the study during the medication free follow-up phase prior to completing 52 weeks (at weeks I, 4, 8, 16 , 43, Weeks in follow-up and 46). Five negative responders were stable without relapse through 52 weeks off medication. None of the positive responders remained relapse free through 52 weeks. Two positive responders were considered dropouts from the study (at weeks 13 and 34). One of these developed prodromal symptoms in the course of follow-up and was assigned to active treatment (under double-blind conditions) according to the protocol and, therefore, could not be followed to relapse. The other who developed prodromal symptoms refused medica tion and was lost to follow-up. Positive responders thus relapsed more often (X2 = 4.9, df = I, P = .027) and more rapidly than negative responders. The mean ± SE relapse for the negative responders was 33.5 ± 4.3 weeks compared to 15.9 ± 3.6 weeks for the posi tive responders. Median ± SE time to relapse was also dramatically different between groups, 30 ± 8 weeks into symptom activators (positive and questionable responders) and nonactivators (negative responders) using a priori criteria. The time to relapse following medication dis continuation is shown. Eighty seven percent of activators relapsed in a mean/median of 15.9/11 weeks; 62% of nonactivators relapsed in a mean/median of 33.5/30 weeks. Thus, symptom activators relapsed in greater proportion, and more rapidly (Mantel-Cox = 8.5, dt = 1, P = .004) than the nonactivator group.
for negative responders and, 11 ± 1.3 weeks for posi tive responders (Figure 3 ). Survival analysis compar ing time to relapse as a function of behavioral response to METHYL revealed a signilicant relationship between positive response and shorter survival (Mantel-Cox = 8 .5, df = I, P = .004).
Additional survival analyses were completed em ploying baseline demographic (age, gender, and so cioeconomic status) and clinical (age of onset, diagno sis, number of prior episodes,duration of stability, neuroleptic dose, symptomatology, and TD status) vari ables as predictors of time to relapse. Baseline sym ptomatology and TD status emerged as signifIcant predictors. Patients with higher baseline scores on the BPRS critical items used to defIne stability and infusion response (conceptual disorganization, bizarre behavior, grandiosity, hostility, suspiciousness, hallucinations, Because METHYL response, symptomatology, and TD were associated with outcome, survival analysis using the Cox proportional hazards model was per formed to examine the combined and independent effects of these variables on time to relapse. The com bined effects of METHYL response, symptomatology, and TD status on time to relapse were highly signifIcant (Global X2 = 16.8, df = 2, P = .0008). When the effects of the three variables were examined individually while controlling for the effects of the others, only symptoma tology (X2 = 4.5, df = 1, P = .035) and METHYL re sponse (X2 = 2.7, df = 1, P = .098) remained associated with time to relapse. Using the Cox proportional haz ards model to predict relapse for the four possible com binations of METHYL response and TD indicated a hi- erarchical relationship, whereas patients with positive METHYL response and TD had the shortest survival time, followed by positive METHYL responders with out TD, and negative METHYL responders with TD; negative METHYL responders without TD had the best outcomes ( Figure 5 ). Of the biochemical variables (PRL, GH, HV A), only basal PRL levels were associated with outcome. Using Cox proportional hazards regression analyses, the preinfusion basal PRL levels in the on-neuroleptic con ditions and off-neuroleptic conditions were associated with risk of relapse. On-neuroleptics, patients with higher basal PRL levels had a greater risk of relapse (X2 = 7.2, df = 1, p = .009); off-neuroleptics, patients with lower basal PRL levels had a greater risk of relapse (X2 = 4.5, df = 1, p = .035). The difference between the on-neuroleptic preinfusion PRL levels and the off neuroleptic preinfusion PRL levels of patients was also examined. Greater decreases in PRL from the on neuroleptic conditions to the off-neuroleptic conditions were associated with greater risk of relapse (X2 = 8.6, dt = 1, p = .003). The pattern of results was not altered by the log transformation of the data done to normal ize the distribution of PRL values.
DISCUSSION
These results demonstrating the relationship between behavioral response to METHYL and to outcome in terms of the likelihood of and time to relapse extremes confrrms our previous findings and is consistent with other reports of an association between behavioral per turbation with indirect acting DA agonists and an in creased risk of relapse in stable patients with schizo phrenia (Angrist et a1. 1981; van Kammen et a1. 1982; Davidson et a1. 1987; Lieberman et a1. 1987b) . These fIndings are consistent with the hypothesis that some clinically stable patients may be physiologically unsta ble and will relapse if they are withdrawn from neu roleptic treatment (or if their maintenance dose is significantly lowered); these patients are susceptible to psychotic symptom provocation by METHYL or other behaviorally active DA agonists. Alternatively, the pe riodicity of schizophrenia may be such that the under lying pathophysiological process precedes and extends beyond the period of acute symptomatology. Conse quently, patients who are verging on relapse or who have recently recovered from an episode may be sus ceptible to pharmacologic perturbation despite their asymptomatic appearance. The latter interpretation is consistent with the hypothesis that susceptibility to the psychotogenic effects of psycho stimulants is a state de pendent phenomenon as demonstrated previously by Janowsky et a1. (1973) and van Kammen et a1. (1982) and reported by our laboratory (Lieberman et a1. 1989; 1993; Jody et a1. 1990) ; however, it is also possible that some patients are persistently susceptible to pharmaco logic perturbation. Duration of stability prior to study en try was not correlated with METHYL response or out come supports this idea; thus, we believe that a sub group of patients is persistently sensitive to DA agonist stimulation, whereas other patients are susceptible only during (or in close temporal proximity to) exacerbation of their illness.
Positive METHYL responders had higher baseline symptom ratings which suggests that these patients may have been more severely ill; however, it should be emphasized that none of the patients were clinically unstable or outside the range of symptomatology nor mally characteristic of the stable ambulatory schizo phrenic population of our institution. Moreover, de spite the statistical significance of the relationship between baseline symptomatology and outcome, it must be emphasized that the diff erences in baseline symptoms among patients who subsequently relapsed quickly were not clinically obvious, or such that patients Dopamine and Relapse in Schizophrenia 115 could have been identified. In this sense, the METHYL procedure served to provoke or amplify clinical features of the disease that were not perceptibly apparent in pa tients under basal conditions.
The other clinical variable that was related to be havioral response to METHYL and outcome was TD. The fact that patients with TD relapsed faster and in greater proportion than patients without TD raised the possibility of an interaction between treatment and course of illness. However, patients with and without TD did not differ on illness course characteristics (du ration of illness, number of prior episodes, medication dose). Because patients with TO were significantly more likely to be positive METHYL responders, suggests that both variables reflect a common pathological process. In clinical terms there are two interpretations of these findings. A subgroup of patients may be predisposed to the development of TD as well as to be highly sensi tive to the psychotogenic effects of METHYL. Alterna tively, patients who develop TD may be, as a conse quence, more sensitive to the behavioral effects of METHYL. Behavioral analogues of TO have been postu lated (Davis et al. 1979; Chouinard et al. 1980) , but never proven (Weinberger et al. 1981; Hunt et al. 1988) . It can not be determined if the outcome of patients in this study was due to idiopathic, or treatment effects, or their interaction; however, it is apparent that outcome in terms of the likelihood and rapidity of relapse could be influenced by DA neural activity that may be reflected by METHYL response and TD. It is our hy pothesis that the functional state of the hyperactive mesocortical and mesolimbic DA neurons that are be lieved to mediate the positive psychotic symptoms of schizophrenia also determine the susceptibility to psy chotogenic response to METHYL and relapse and that this is a genetically determined trait (Piazza et al. 1989) . These neural systems have previously been shown to be sensitive to stress and pharmacologic stimulation that enhances DA neurotransmission (Kalivas et a1. 1988) ; Lee et al. 1988; Roth et al. 1988) . Csernansky et al. (1991) has proposed a model in which ventrotegmental DA neurons modulate the function of a limbic circuit in volving the ventromedial caudate, nucleus accumbens, amygdala, hippocampus, and cingulate cortex. In this model, environmental or pharmacologic perturbations that acutely increases DA neurotransmission produce disinhibition of the limbic circuit that in turn leads to expression of psychosis. We further speculate that pa tients with this physiologic trait have an increased sus ceptibility to develop TD with sufficient neuroleptic ex posure. Previously reported data (Csernansky et al. 1986; Newcomer et al. 1992 ) are consistent with this hy pothesis. They found that positive symptom ratings were higher in patients with TO and correlated inversely with plasma PRL. Moreover, in the current study, lower basal PRL of neuroleptics and a greater decline in PRL with neuroleptic withdrawal was associated with greater relapse risk. This may reflect emergent OA ac tivity in the tuberoinfundibular system following neu roleptic withdrawal (and exerts inhibitory effects on PRL) and parallels similarly increased OA activity in the mesolimbic and mesocortical systems. The association between higher basal PRL on neuroleptics and a greater risk of relapse might be the result of a neuroleptic effect. More severely ill patients may receive higher neurolep tic doses that produce greater PRL elevation. In this way, neuroleptic dose may more accurately represent the patient's true illness severity than symptoms that are suppressed by treatment. Such patients might be expected to have a higher risk of relapse; however, neu roleptic dose itself was not associated with relapse risk. Thus, the on-medication PRL association with outcome may reflect a more complex interaction of drug-patient factors in terms of pharmacologic responsivity in the pituitary rather than drug dose alone (Lieberman et al. 1986a) .
Also, partially consistent with our hypothesis was the observation that basal pHV A in the off-neuroleptic condition was higher in patients who activated with METHYL. This, as did the PRL data, suggests that OA neurons may have been unsuppressed following neu roleptic withdrawal. The relationship between pHV A and outcome may have failed to reach signifIcance be cause of the limited sample size on whom pHV A sam ples were available.
In conclusion, behavioral response to METHYL, and to a lesser extent, TO development with sustained neuroleptic exposure provide a bioassay of CNS OA dysfunction in schizophrenia.
When this study was conducted, the question of whether stable patients with chronic schizophrenia, particularly those with side effects including TO, could be safely withdrawn from neuroleptic maintenance treatment had not yet been answered. The targeted in termittent maintenance treatment strategy was believed to be viable for the long term management of patients. Because of recent studies (Jolley et al. 1989; Carpenter et al. 1990; Herz et al. 1991; Schooler et al. 1993) , it is now clear that continuous antipsychotic drug main tenance is the preferred mode of treatment for multiepi sode, chronic, schizophrenic patients. Because medi cation discontinuation is rarely indicated in the long term management of schizophrenic patients, the main practical implementation of provocative tests with psy chostimulant drugs will be in identifying candidates for dose reduction, or for patients who insist on discon tinuing medication. In such cases, the test results could be a useful deterrent to patients.
